Bayer Receives U.S. FDA Fast Track Designation for Asundexian Stroke Program

Donnerstag, 10.02.2022 08:40 von PLX

• (PLX AI) – Bayer gets U.S. FDA Fast Track designation for asundexian Stroke Program.
• • Drug is potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke
• • Asundexian is currently in Phase II clinical trials in all three indications either as a standalone therapy, or in combination with anti-platelet therapy
• • Inhibition of FXIa by asundexian is hypothesized to provide protection from thrombotic events without increasing the risk of bleeding